Navigation Links
Breakthrough in Migraine Treatment
Date:11/8/2011

LIEGE, Belgium, November 8, 2011 /PRNewswire/ --

PREMICE clinical trial proves Cefaly® medical device efficacy in migraine prevention and points out that Cefaly® has the best safety-efficacy ratio compared to other treatments.

On Monday 7th of November a press conference took place in Liege Science Park. Professor Jean Schoenen, principal investigator, neurologist and professor at Liege University (Belgium) presented the results of PREMICE (Prevention Migraine Cefaly) a multicenter randomized double-blind placebo controlled clinical trial for migraine prevention with the Cefaly® neurostimulator.

The clinical trial was conducted in 5 Belgian university hospitals on 67 patients. The results prove the efficacy of the Cefaly® compared to placebo for migraine prevention. At 3 months of treatment the 50% responder rate was significantly greater in the Cefaly® group (38,1%) than in the placebo group (12,1%). Seventy percents of patients declared they were satisfied or very satisfied with the Cefaly® treatment. The drug consumption reduction is very impressive in the Cefaly® group (-37%) compared to the placebo group (+0.5%). Cefaly® responder group drug consumption reduction was -75%!

Without noticeable side effects or contraindications, Cefaly® is very safe. Cefaly® has a similar efficacy than preventative drugs, but without side effects. Consequently, Cefaly® has the best safety-efficacy ratio of all migraine treatments.

Prof. Schoenen: "This clinical trial has been implemented according to the highest quality standard and it proves that Cefaly® is efficient for migraine prophylaxis. Efficacy is similar with the most efficient preventative drugs but with the great advantage of having no side effects."

Cefaly® is an innovative medical device protected by a series of patents. This is the first cranial external neurostimulation device on the market. Cefaly® neurostimulation is applied to the upper branch of the trigeminal nerve. A self-adhesive electrode is applied on the forehead and the device is placed on this electrode in the position of a pair of glasses. Very accurate pulses are transmitted through the electrode to the nerve endings of the trigeminal nerve.

STX-Med Company is a startup based in Liege (Belgium), which launched the Cefaly® technology project in 2005. The company STX-Med is ISO Medical. Cefaly® device has the medical CE-marked. It is available on the European market for 295 € and in Canada as well.

http://www.cefaly.com/


'/>"/>
SOURCE STX-Med
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genetic Profile Identified for Alzheimers Patients Showing Heightened Response to Acceras Breakthrough Product Axona®
2. Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S.
3. SensoScientific Awarded Contract by Premier Health Care Alliance for its Breakthrough WI-FI Temperature Monitoring System
4. Major Diagnostic Breakthrough in Multiple Sclerosis Achieved with Advanced FONAR UPRIGHT® MRI
5. Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis
6. Aging-in-Place Research Breakthroughs To Be Presented At Wireless Health 2011 Conference
7. Molecular Devices Releases Breakthrough TUNE Technology, Now Part of the SpectraMax® Paradigm® Multi-Mode Microplate Detection Platform
8. aTyr Pharma Expands Leadership Team to Advance New Breakthrough Medicines Based on Physiocrine Biology
9. Report on HIV Prevention Research Funding Says New Investment Critical to Capitalize on HIV Prevention Research Breakthroughs
10. FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
11. CT Scans Unleash a Breakthrough in Catching Early Stage Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... JERUSALEM , May 23, 2016 ... DNA for detection of multiple diseases; ,Technology to be ... Yissum Research Development Company of the ... entered into a research agreement with Aurum Ventures MKI, the ... the development of a new diagnostic approach for early ...
(Date:5/22/2016)... , May 23, 2016 ... develop its anti-fibrotic and anti-inflammatory compound DS102 in ... as in non-alcoholic steatohepatitis (NASH) patients. ... significantly sequestered in lung tissue and has bronchodilatory, ... after oral administration. The Company will publish further ...
(Date:5/20/2016)... 2016 ReportsnReports.com adds "Plaque ... market research report with comprehensive information on the ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... NutraPre today announced the ... pregnant women to prevent morning sickness and promote overall heath. Engineered with advanced ... and taste of water. , “Imagine a pregnancy without morning sickness,” NutraPre CEO ...
(Date:5/23/2016)... Angeles, CA (PRWEB) , ... May 23, 2016 , ... ... surgeons have noted that, less than 1% of United Kingdom residents who could benefit ... UK’s National Health Service (NHS) increases the number of bariatric procedures it offers to ...
(Date:5/23/2016)... ... , ... NYDNRehab, a New York City-based physical therapy clinic , is ... this type of technology, which was developed by world-renowned researcher Dr. Christopher Powers of ... , With over 10 million sport injuries per year in the United ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Society for Women’s Health ... to move on from that role. , “No one in Washington led the way ... said SWHR Founder Florence Haseltine, MD, PhD. “We offer our deep gratitude to Phyllis ...
(Date:5/23/2016)... , ... May 23, 2016 , ... ... care to residents of Westchester County for over 24 years, recently hosted its ... community members joined HOW for two remembrance ceremonies, each concluding with the release ...
Breaking Medicine News(10 mins):